Triple Therapy and Other Treatments for H. pylori. The 2012 Maastricht Consensus (an annual meeting of the European Helicobacter Study Group) reported that standard triple therapy cure rates for H. pylori are at around 70% when all research is collated. In this study pantoprazole-based triple therapy eradi-cated H. pylori in 86% (per protocol) of patients. In the last few years, a triple therapy including a levofloxacin–amoxycillin combination has been proposed for either first-line or rescue therapy regimen to cure H. pylori infection , , , , , . Clarithromycin triple therapy consists of a PPI, clarithromycin (Biaxin), and amoxicillin or metronidazole (Flagyl) for 14 days. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Clarithromycin, an antibiotic ; Amoxicillin or Tinidazole, also antibiotics; A proton pump inhibitor to reduce stomach acid Read our disclaimer for details. Therefore, H. pylori management in the clinical practice remains a challenge for the physicians. The eradication rate of Helicobacter pylori (H. pylori) with triple therapy which was considered as standard first-line treatment has decreased to 70–85%. The aim of this study is to compare 7-day triple therapy versus 10-day sequential therapy as the first line treatment. Standard H pylori triple therapy using two antibiotics and a proton pump inhibitor is now widely regarded as having unacceptable failure rates. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. H pylori regimens include triple therapy, sequential therapy (patient is given one treatment, followed by another), quadruple therapy, and levofloxacin-based triple therapy (TABLE 3). Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection. Given that pantoprazole was a new drug in this field of treatment a 10-day course seemed most appropriate. One of the more common treatments for H. pylori is known as triple therapy, which includes 1-2 weeks of three different medications (9, 10). H. pylori therapy may be insufficient. Based upon these data, a treatment duration of 10–14 days is recommended for bismuth quadruple therapy. This eradication was paralleled by a marked reduction in The most recent network meta-analysis of H. pylori regimens also found that 10–14 days of bismuth quadruple therapy was superior to 7 days of clarithromycin triple therapy (85 vs. 73%, RR=1.17; 95% CI=1.12–1.21) .